Botulinum toxin in the treatment of muscle pain;Der einsatz von botulinum-toxin in der therapie von muskelschmerzen

Schmerz

Volumn 17, Issue 6, 2003, Pages 450-458

  Benecke, R ^a   Dressler D ^a   Kunesch, E ^a   Probst, T ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

Botulinum toxin; Dystonia; Myofascial pain syndrome; Spasticity

Indexed keywords

BOTULINUM TOXIN; BOTULINUM TOXIN A; MUSCLE RELAXANT AGENT;

ANALGESIC ACTIVITY; DYSTONIA; EVIDENCE BASED MEDICINE; FIBROMYALGIA; HUMAN; INJECTION; MEDICOLEGAL ASPECT; MYOFASCIAL PAIN; NEUROMODULATION; PATHOPHYSIOLOGY; REVIEW; SPASTICITY; CLINICAL TRIAL; MUSCLE DISEASE; MYOSITIS; PAIN;

BOTULINUM TOXIN TYPE A; CLINICAL TRIALS; HUMANS; MUSCULAR DISEASES; MYOSITIS; NEUROMUSCULAR AGENTS; PAIN;

EID: 1542570264     PISSN: 0932433X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00482-003-0263-5     Document Type: Review

References (71)

1. Acquadro MA, Borodic GE (1994) Treatment of myofascial pain with botulinum A Toxin Anesthesiology 80:705-706
2. Ärztliche Zentralstelle für Qualitätssicherung (1999) Leitlinien-Info. ÄZQ-Schriftenreihe, Bd 1. Zuckerschwerdt, München, S 62-68
3. Alo KM, Yland MJ, Kramer DL et al. (1997) Botulinum toxin in the treatment of myofascial pain. The Pain Clinic 10:107-116
4. Aoki K, Weber J, Patten P et al. (2000) United States Patent Number 6113915, Sep. 5
5. Aoki K (2001) Pharmacology and immunology of botulinum toxin serotypes. J Neurol 248 [Suppl 1]:3-10
6. Asherson RA, Pascoe L (2001) The use of botulinum toxin-A in the treatment of patients with fibromyalgia. J Rheumatol 28:1740
7. Bakheit AM, Pittstock S, Moore AP et al. (2001) A randomized, double-blind, plazebo-controlled study of the efficacy and safety of botulinum toxin type A in upper limb spasticity in patients with stroke. Eur J Neurol 8:559-565
8. Barwood S, Baillieu C, Boyd R et al. (2000) Analgesic effects of botulinum toxin A: a randomized, plazebo-controlled clinical trial. Dev Med Child Neurol 42:116-121
9. Behari M (1999) Botulinum toxin in the treatment of writer's cramp. J Assoc Physicians India 47:694-698
10. Benecke R (1994) Botulinum toxin treatment in spasticity of lower extremities. In: Jankovic J, Hallett M (eds) Therapy with Botulinum Toxin. Marcel Dekker, New York, S 463-473
11. Bhakta B, Cozens JA, Bamford JM, Chamberlain MA (1996) Use of botulinum toxin in stroke patients with severe upper limb spasticity. J Neurol Neurosurg Psychiatry 61:30-35
12. Bhakta B, Cozens JA, Chamberlain MA, Bamford JM (2000) Impact of botulinum toxin type A on disability and career burden due to arm spasticity after stroke: a randomized double blind plazebo controlled trial. J Neurol Neurosurg Psychiatry 69:217-221
13. Blasi J, Chapman ER, Link E et al. (1993) Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25. Nature 265:160-163
14. Brin MF, Fahn S, Moskowitz C et al. Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm. Adv Neurol 1988;50:599-608
15. Brin MF, Lew M, Adler C et al. (1999) Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia. Neurology 53:1431-1438
16. Carruthers J, Carruthers A (1992) Treatment of glabellar frown lines with C. botulinum-A exotoxin. J Dermatol Surg Oncol 18:17-21
17. Carruthers A, Langtry JA, Carruthers J, Robinson G (1999) Improvement of tension-type headache when treating wrinkles with botulinum toxin A injections. Headache 39:662-665
18. Chalkiadaki A, Rohr UP, Hefter H (2001) Frühe Schmerz-reduktion in der Therapie von Spastik nach einmaliger Botulinustoxin-A-Injektion. Dtsch Med Wochenschr 126:1361-1364
19. Chan J, Brin M, Fahn S (1991) Idiopathic cervical dystonia: clinical characteristics. Mov Disord 6:119-126
20. Cheshire WP, Abashian SW, Mann JD (1994) Botulinum toxin in the treatment of myofascial pain syndrome. Pain 59:65-69
21. Comella C, Shannon K, Jaglin J. Extensor truncal dystonia: Successful treatment with botulinum toxin injections. Mov Disord 1998;13:552-555
22. Cordiviari C, Misra V, Catania S, Lees A (2001) Treatment of dystonic clenched fist with botulinum toxin. Mov Disord 16:907-913
23. Cui ML, Khanijou S, Rubino J, Aoki KR (2000) Botulinum toxin A inhibits the inflammatory pain in the rat formalin model. Society for Neuroscience Annual Meeting, New Orleans Poster 246.2
24. Diaz JH, Gould HJ (1999) Management of post-thoracotomy pseudoangina and myofascial pain with botulinum toxin. Anesthesiology 91:877-899
25. Dolly J, Ashton A, Evans D et al. (1987) Molecular action of botulinum neurotoxins: role of acceptors in targetting to cholinergic nerves and in the inhibition of the release of several transmitters. In: Dowdall M, Hawthorne J (eds) Cellular and molecular basis of cholinergic function. Ellis Horwood, Chichester, pp 17-535
26. Dressler D, Argyrakis A, Schönle PW et al.(1996) Botulinum Toxin Therapie in der Rehabilitationsneurologie. Nervenarzt 67:686-694
27. Dressler D (2000) Botulinum Toxin Therapy. Thieme, Stuttgart New York
28. Dressler D, Saberi FA, Benecke R (2002) Botulinumtoxin type B for treatment of axillar hyperhidrosis J. Neurol 249:1729-1732
29. Dunne JW, Heye N, Dunne SL (1995) Treatment of chronic limb spasticity with botulinum toxin. J Neurol Neurosurg Psychiatry 58:232-235
30. Filippi GM, Errico P, Santarelli R et al. (1993) Botulinum A toxin effects on rat jaw muscle spindles. Acta Otolaryngol 113:400-404
31. Foster L, Clapp L, Erickson M, Jabbari B (2001) Botulinum toxin A and chronic low back pain: a randomized, double-blind study. Neurology 56:1290-1293
32. Galate JF, Childers MK, Gnatz S (1997) Effectiveness of botulinum toxin in refractory piriformis muscle syndrome. Arch Phys Med Rehabil 78:1041
33. Grazko MA, Polo KB, Jabbari B (1995) Botulinum toxin A for spasticity, muscle spasms, and rigidity. Neurology 45:712-717
34. Hagenah R, Benecke R, Wiegand H (1977) Effects of type A Botulinum toxin on the cholinergic transmission at spinal Renshaw cells and on the inhibitory action at la inhibitory interneurones. Naunyn Schmiedeberg's Arch Pharmacol 299:267-272
35. Hilker R, Schischniaschvili M, Ghaemi M et al. (2001) Health related qualitiy of life is improved by botulinum neurotoxin type A in long term treated patients with focal dystonia. J Neurol Neurosurg Psychiatry 71:193-199
36. Hong C, Simons D (1998) Pathophysiologic and electrophysiologic mechanisms of myofascial trigger points. Arch Phys Med Rehabil 79:863-872
37. Hubbard D, Berkoff G (1993) Myofascial trigger points show spontaneous needle EMG activity. Spine 18:1803-1807
38. Hyman N, Barnes M, Bhakta B et al. (2000) Botulinum toxin (Dysport®) treatment of hip adductor spasticity in multiple sclerosis: a prospective, randomised, double-blind, plazebo-controlled, dose ranging study. J Neurol Neurosurg Psychiatry 68:707-712
39. Jordan SE, Ahn SS, Freischlag JA et al. (2000) Selective botulinum chemodenervation of the scalene muscles for treatment of neurogenic thoracic outlet syndrome. Ann Vasc Surg 14:365-369
40. Jost W, Kohl A (2001) Botulinum toxin: evidence-based medicine criteria in rare indications. J Neurol 248 [Suppl 1]:39-44
41. Kelm S, Gerats G, Chalkiadaki A, Hefter H (2001) Reduction of pain and muscle spasms by botulinum toxin A. Nervenarzt 72:302-306
42. Krack P, Hornig C, Dorndorf W. Resolution of chronic tension-type headache after botulinum toxin treatment of idiopathic blepharospasm. Mov Disord 1995;10:388
43. Kunig G, Pogarell O, Oertel WH (1998) Facial pain in a case of cranial dystonia: a case report. Cephalagia 18:709-711
44. Lew MF, Adornato BT, Duane DD et al. (1997) Botulinum toxin type B: A double-blind, plazebo-controlled, safety and efficacy study in cervical dystonia. Neurology 49:701-707
45. Lindeboom R, Brans J, Aramideh M et al. (1998) Treatment of cervical dystonia: A comparison of outcome measures for outcome assessment. Mov Disord 13:706-712
46. Lutze MA (2000) CT-gestützte Injektionen von Botulinumtoxin A beim myofaszialen Schmerzsyndrom. Schmerz [Suppl 1]:91
47. Mense S (1999) Neurobiologische Grundlagen von Muskelschmerz. Schmerz 13:3-17
48. Monsivais JJ, Monsivais DB (1996) Botulinum toxin in painful syndromes. Hand Clin 12:787-789
49. Nouwen A, Bush C (1984) The relationship between paraspinal EMG and chronic low back pain. Pain 20:109-123
50. Pacchetti C, Albani G, Martignoni E et al. (1995) "Off" painful dystonia in Parkinson's disease treated with botulinum toxin. Mov Disord 10:333-336
51. Pal PK, Samii A, Schulzer M et al. (2000) Head tremor in cervical dystonia. Can J Neurol Sci 27:137-142
52. Paulson GW, Gill W (1996) Botulinum toxin is unsatisfactory therapy for fibromyalgia. Mov Disord 11:459
53. Pierson SH, Katz DI, Tarsy D (1996) Botulinum toxin A in the treatment of spasticity: functional implications and patient selection. Arch Phys Med Rehabil 77:717-721
54. Poewe W, Deuschl G, Nebe A et al. (1998) What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, plazebo controlled dose ranging study using dysport. J Neurol Neurosurg Psychiatry 64:13-17
55. Porta M, Perretti A, Gamba M, Luccarelli G, Fornari M (1998) The rationale and results of treating muscle spasm and myofascial syndromes with botulinum toxin type A. Pain Digest 8:346-352
56. Porta M (2000) A comparative trial of botulinum toxin type A and methylprednisolone for the treatment of myofascial pain syndrome and pain from chronic muscle spasm. Pain 85:101-105
57. Probst T, Dressler D, Benecke R, Kunesch E (2002) Botulinumtoxin in der Schmerztherapie. Akt Neurol 29:389-401
58. Puffer E, Lomneth R, Sarkar H, Singh B (2001) Differential roles of developmentally distinct SNAP-25 isoforms in the neurotransmitter release process. Biochemistry 40:9374-9378
59. Reichel G (2001) Botulinum toxin for treatment of spasticity in adults. J Neurol 248 [Suppl 1]:25-27
60. Rosales RL, Arimura K, Ikenaga S, Osarne M (1996) Extrafusal and intrafusal muscle effects in experimental botulinum toxin A injection. Muscle Nerve 19:488-496
61. Sala C, Adreose J, Fumagalli G et al. (1995) Calcitonin gene-related peptide: possible role in formation and maintenance of neuromuscular junctions. J Neurosci 15:520-528
62. Scott AB (1980) Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. J Pediatr Ophthalmol Strabismus 17:21-25
63. Scottish intercollegiate guidelines network SIGN Guidelines - An introduction to SIGN Methodology for the development of evidence-based clinical guidelines. Edinburgh: SIGN Publication Number 39. SIGN Secretariat. Royal College of Physicians
64. Simons DG, Mense S (1998) Understanding and measurement of muscle tone as related to clinical muscle pain. Pain 75:1-17
65. Suzuki N, Hardebo JE, Kahrstrom J et al. (1990) Neuropeptide Y co-exists with vasoactive intestinal polypeptide and acetylcholine in parasympathetic cerebrovascular nerves originating in the sphenopalatine, otic and internal carotid ganglia of the rat. Neuroscience 36:507-519
66. Tarsy D, First ER (1999) Painful cervical dystonia: clinical features and response to treatment with botulinum toxin. Mov Disord 14:1043-1045
67. Welch M, Purkiss J, Foster K (2000) Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. Toxicon 38:245-258
68. Wheeler AH, Goolkasian P, Gretz SS (1998) A randomized, double-blind, prospective pilot study of botulinum toxin injection for refractory, unilateral, cervicothoracic, paraspinal, myofascial pain syndrome. Spine 23:1662-1666
69. Wiegand H, Erdmann G, Wellhöner HH (1976) 125 I-labelled botulinum A neurotoxin: pharmacokinetics in cats after intramuscular injection. Naunyn Schmiedeberg's Arch Pharmacol 292:161-165
70. Wissel J, Muller J, Dressnandt J et al. (2000) Management of spasticity associated pain with botulinum toxin A. J Pain Symptom Manage 20:44-49
71. Yue SK (1995) Initial experience in the use of botulinum-toxin A for the treatment of myofascial related muscle dysfunctions. J Musculoskelet Pain 3 [Suppl 1]:22